---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-25-000022"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:51:54.462212+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Entrada reports Q1 net loss of $17.3M, gets EU clearance for DMD exon 44 trial, cuts workforce 20%

## Summary
- Net loss of $17.3M in Q1 2025 vs net income $23.5M Q1 2024; collaboration revenue fell to $20.6M from $59.1M.
- EU authorization received for Phase 1/2 MAD study (ELEVATE-44-201) of ENTR-601-44; Q2 2025 initiation on track.
- Additional DMD programs: ENTR-601-45 study initiation Q3 2025; ENTR-601-50 regulatory submission H2 2025.
- Workforce reduced ~20% to focus on DMD clinical pipeline and key preclinical programs; cash runway into Q2 2027 ($382.5M).
- Vertex-partnered VX-670 for DM1 continues enrollment in MAD portion of Phase 1/2 trial.

## SEC filing metadata
- accession: 0001689375-25-000022
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000022/0001689375-25-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000022/trda-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-25-000022
- JSON: https://secwatch.observer/filing/0001689375-25-000022.json
- Plain text: https://secwatch.observer/filing/0001689375-25-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.